Market Research Logo

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2015

Introduction
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview
Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
Drug Profiles
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Recent Pipeline Updates
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2015
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Affimed Therapeutics AG, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Altor BioScience Corporation, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Array BioPharma Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AstraZeneca Plc, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bexion Pharmaceuticals, LLC., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Calithera Biosciences, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cantargia AB, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectis S.A., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellular Biomedicine Group, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ceronco Biosciences, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Conkwest, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by DiNonA Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by EpiZyme, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Erytech Pharma SA, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eureka Therapeutics, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Fate Therapeutics, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gamida Cell Ltd., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Hangzhou Minsheng Pharmaceutical Group Co.,Ltd, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by iDD biotech SAS, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Immunomedics, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Incyte Corporation, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Interprotein Corporation, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jasco Pharmaceuticals, LLC., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Johnson & Johnson, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Juno Therapeutics Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kiadis Pharma B.V., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kite Pharma, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by medac GmbH, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by MedImmune, LLC, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Merck & Co., Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Mirna Therapeutics, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Novartis AG, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NuCana BioMed Limited, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Omeros Corporation, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Onconova Therapeutics, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OriBase Pharma, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfenex Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfizer Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pharma Mar, S.A., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pharmacyclics, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Polyphor Ltd., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Portola Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Priaxon AG, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Quimatryx, S.L., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sanofi, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sareum Holdings Plc, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sellas Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sigma-Tau S.p.A., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Syndax Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Theravectys S.A., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tolero Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Verastem, Inc., H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Xenetic Biosciences plc, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics - Recent Pipeline Updates, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..1), H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..2), H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..3), H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..4), H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, H1 2015
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2015
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2015’, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;